HAH. Richard Alexander

H. Richard Alexander

*This is an algorithmically generated author record based on publicly available information.

H. Richard Alexander has a total of 135 co-authors. Here are the top co-authors by number of shared publications:

  • Steven K. Libutti

    Department of Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10467, USA

    6 shared publications
  • James F. Pingpank

    Surgical Oncology (Pittsburgh), Departments of Surgery, University of Maryland School of Medicine, Baltimore, and the University of Pittsburgh Medical Center, Pittsburgh

    5 shared publications
  • Sheelu Varghese

    5 shared publications
  • David L. Bartlett

    Surgical Oncology (Pittsburgh), Departments of Surgery, University of Maryland School of Medicine, Baltimore, and the University of Pittsburgh Medical Center, Pittsburgh

    4 shared publications
  • Nader Hanna

    The Divisions of General and Oncologic Surgery (Maryland)

    4 shared publications
  • Steven K. Libutti

    Surgery Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland

    4 shared publications

Latest Publications

  • 217 - Comparison of Perioperative Chemotherapy vs. Postoperative Chemoradiation Therapy for Adenocarcinoma of the Gastric Cardia: An Analysis of the National Cancer Database

    by Mihir M. Shah, Rachel E. NeMoyer, Stephanie H. Greco, Yong Lin, Miral S. Grandhi, Darren Carpizo, Parisa Javidian, Salma K. Jabbour, David A. August, H. Richard Alexander, et al.

  • Open Access

    Diagnosis and management of patients with malignant peritoneal mesothelioma

    by H. Richard Alexander Jr, Allen P. Burk

    Diagnosis and management of patients with malignant peritoneal mesothelioma


  • Open Access

    Rapid progression of a pregnancy-associated intra-abdominal desmoid tumor in the post-partum period

    by David Hanna, Michail Magarakis, William S. Twaddell, Richard H. Alexander, Susan B. Kesmodel

    INTRODUCTION: The clinical behavior of desmoid tumors can be unpredictable, particularly when they arise in the ante-partum or post-partum period. We present a case of an intra-abdominal desmoid tumor that was identified in the ante-partum period, progressed rapidly in the post-partum period, and was subsequently resected. PRESENTATION OF CASE: The patient is a 19 year-old female who was found to have a 12 cm intra-abdominal mass on a fetal assessment ultrasound. The decision was made to observe the patient and monitor the mass for growth. However, the mass rapidly grew in the post-partum period. The patient was transferred to our institution after an exploratory laparotomy revealed a large intra-abdominal mass emanating from the small bowel mesentery. The 30 cm × 24 cm × 16 cm mass was successfully resected with negative margins, and the pathologic diagnosis of desmoid tumor was confirmed. The patient had an uncomplicated post-operative course and was discharged on post-operative day 6. DISCUSSION: The majority of pregnancy-associated desmoid tumors are in the abdominal wall, arising from the rectus abdominus muscle or from previous Cesarean section scars. These tumors may spontaneously regress in the post-partum period and therefore, patients with these tumors are often observed. Close follow-up is important so that rapid tumor progression, which may lead to unresectability, can be identified and managed appropriately. CONCLUSION: A patient with a rare case of a giant pregnancy-associated, intra-abdominal desmoid tumor that rapidly progressed in the post-partum period and was successfully treated with surgical resection with negative margins. Highlights:


  • Isolated hepatic perfusion for patients with liver metastases

    by Srinevas K. Reddy, Susan B. Kesmodel, H. Richard Alexander

    Up to 80% of colorectal, melanoma, and neuroendocrine liver metastases are unresectable due to excessive tumor burden. Isolated hepatic perfusion (IHP) administers intensive therapy to the liver while limiting systemic toxicity and thus may have an important role in the management of unresectable liver metastases. This review s describes the development of IHP, initial clinical results, open and percutaneous IHP techniques, and contemporary long-term treatment outcomes. IHP with melphalan or tumor necrosis factor α (TNFα) has been shown to achieve hepatic response rates of greater than 50% with progression-free survival of greater than 12 months among patients with refractory ocular melanoma liver metastases. The only series describing outcomes of IHP for neuroendocrine liver metastases notes an overall response rate of 50% and a median actuarial overall survival of 48 months after IHP treatment with melphalan or TNFα. The majority of studies that have evaluated IHP have been performed in patients with colorectal cancer liver metastases (CRCLM). In aggregate, survival results from retrospective studies and phase I/II clinical trials suggest that IHP demonstrated no significant survival benefit compared with systemic chemotherapy alone as first-line therapy. In contrast, IHP does improve outcomes relative to that provided by second-line chemotherapy for CRCLM, with overall response rates of 60% and median duration of liver response of 12 months. Continued evaluation of IHP for unresectable liver metastases is necessary to establish its role in multidisciplinary treatment approaches.


  • Regulatory Considerations in Human Subjects Research

    by H. Richard Alexander, Edward Sausville, Shannon Decker


  • Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma

    by H. Richard Alexander, David L. Bartlett, James F. Pingpank, Steven K. Libutti, Richard Royal, Marybeth S. Hughes, Matthew Holtzman, Nader Hanna, Keli Turner, Tatiana Beresneva, et al.


  • Assessment of Neoadjuvant Chemotherapy on Operative Parameters and Outcome in Patients with Peritoneal Dissemination from High-Grade Appendiceal Cancer

    by Keli M. Turner, Nader N. Hanna, Yue Zhu, Ajay Jain, Susan B. Kesmodel, Rebecca A. Switzer, LaToya M. Taylor, H. Richard Alexander

    Background High-grade appendiceal adenocarcinoma is a rare malignancy with propensity for peritoneal metastases (PM). The impact of neoadjuvant chemotherapy on operative cytoreduction (CRS) and...


  • Analysis of toxicity and outcomes in patients undergoing hyperthermic isolated hepatic perfusion with melphalan for metastatic melanoma to the liver.

    by Benjamin Golas, Deepa Magge, Amer H. Zureikat, Herbert Zeh, H. Richard Alexander, Steven K. Libutti, Richard E. Royal, Marybeth S. Hughes, Matthew Peter Holtzman, Kiran Turaga, et al.

    178 Background: Ocular melanoma (OM) has an annual incidence of 3500 to 4000 patients per year, with liver metastases (LM) accounting for the sole or dominant site of metastases in more than 80% of patients. For patients with LM, median survival is reported to be 2 to 7 months, with an estimated 1-year survival of 10%. We present results utilizing liver directed therapy with high-dose melphalan administered via hypertermic isolated hepatic perfusion (IHP) for patients with unresectable LM from OM. Methods: Between 10/1994 and 6/2012, 105 pts with unresectable LM underwent a 60 min hyperthermic (IHP) with melphalan (1-2 mg/kg IBW). IHP included hepatic isolation at laparotomy with inflow via a cannula in the gastroduodenal artery and outflow via a cannula in the isolated retrohepatic vena cava (IVC). Patients were followed for toxicity, radiographic response (WHO criteria), and hepatic progression-free (HPFS) and overall survival (OS). HPFS and OS probabilities were calculated by Kaplan-Meier. Results: There were 51 males and 54 females (mean age: 50 yr [range: 21-76]) with unresectable OM LM (median # metastases: 26 [range: 3-50]; median percent liver replaced by tumor: 22%). There were 3 operative/treatment mortalities (2.9%). There were 62 responses (CR: n=6, PR: 56) in 102 evaluable patients (61%). For all treated patients, median OS was 12 months (range: 1 to 115 months) with 2 and 3-yr survival of 31% and 21%, respectively. Conclusions: IHP with melphalan results in marked tumor regression and prolonged OS in patients with high hepatic tumor burden from metastatic OM. Although this is a non-randomized trial, response to IHP is associated survival superior to that reported with alternative therapies.

  • Radiation in the management of pancreatic neuroendocrine tumors.

    by Bertram W. Maidment, Trevor Ellison, Joseph M. Herman, Navesh K Sharma, Dan Laheru, William Regine, Aaron Tyler Wild, Kelly Olino, Ralph H. Hruban, John L Cameron, et al.

    335 Background: Radiation therapy (RT) has not historically been incorporated into multidisciplinary management of pancreatic neuroendocrine tumors (PNTs). We provide a two-institution series of patients with PNTs who were treated with external beam RT either neoadjuvantly to attempt down-staging for surgery, or in the setting of post-surgical recurrence. Our objective was to assess treatment response and outcomes in this cohort of patients. Methods: We identified eleven patients with a pathologic diagnosis of PNT from 2006-2011 who received external beam RT to the primary tumor or resection bed. Each institution’s electronic medical record was used to evaluate patient demographics, disease characteristics, treatment regimens and tolerance, radiographic response, and survival. Results: Our series consists of eleven patients (6 men, 5 women) with a mean age of 57 years (range 37-72 years). All had biopsy proven PNT and were clinically T3 (n=3) or T4 (n=8), M0. Five patients were clinically node positive. All patients received RT to the primary tumor or resection bed to a median dose of 50.4 Gy. Seven patients received concurrent chemotherapy with capecitabine at a median dose of 1000mg/m2 bid. Nine patients were treated definitively for locally advanced disease, two of whom subsequently underwent surgical resection. Two patients were treated to palliate post-resection recurrence. Initial radiographic response to RT included 2 complete responses (CR), 2 partial responses (PR), 4 stable disease, 3 progressive disease (PD). Two patients were classified as PD due to the development of distant metastases less than 2 months after completing RT. Two grade 3 toxicities were documented (one early, one late). At a median follow-up of 30.4 months, three patients had died with evidence of PD, two had died without evidence of PD, three were alive with metastases, and three were alive without evidence of disease progression (1 stable, 1 PR, 1 CR). From the start of RT, median overall survival was 32.1 months; progression free survival was 14.6 months. Conclusions: RT may have the potential to convert PNTs from locally-advanced to resectable. RT may also increase local control of PNTs. Consideration should be given to the use of RT in prospective trials of PNT treatment.


  • Current Concepts in the Evaluation and Treatment of Patients With Diffuse Malignant Peritoneal Mesothelioma

    by Keli Turner, Sheelu Varghese, H. Richard Alexander

    Diffuse malignant peritoneal mesothelioma (DMPM) is a rare and ultimately fatal cancer that was first recognized and described a century ago. It is a diffuse primary malignant condition arising from the mesothelial lining of the peritoneum, and its natural history is hallmarked by a propensity to progress almost exclusively within the abdominal cavity throughout the entire course of disease. Patients afflicted with DMPM most commonly present with nonspecific abdominal symptoms that lead to diagnosis when the condition is relatively advanced. Historically, median overall survival for patients with DMPM without treatment is very short, averaging 6 months. Systemic chemotherapy using pemetrexed and cisplatin has an overall response rate of approximately 25% and a median overall survival of approximately 1 year. Many institutional reports have shown that in selected patients, operative cytoreduction and hyperthermic intraoperative peritoneal chemotherapy using cisplatin or mitomycin C is associated with long-term survival. Recent studies on the molecular biology of DMPM have yielded new insights relating to the potentially important role of the phosphatidylinositol 3-kinase/mammalian target of rapamycin and epidermal growth factor receptor pathways in this disease, which may translate into new therapeutic options for patients with DMPM. Diffuse malignant peritoneal mesothelioma (DMPM) is a rare and ultimately fatal cancer that was first recognized and described a century ago. It is a diffuse primary malignant condition arising from the mesothelial lining of the peritoneum, and its natural history is hallmarked by a propensity to progress almost exclusively within the abdominal cavity throughout the entire course of disease. Patients afflicted with DMPM most commonly present with nonspecific abdominal symptoms that lead to diagnosis when the condition is relatively advanced. Historically, median overall survival for patients with DMPM without treatment is very short, averaging 6 months. Systemic chemotherapy using pemetrexed and cisplatin has an overall response rate of approximately 25% and a median overall survival of approximately 1 year. Many institutional reports have shown that in selected patients, operative cytoreduction and hyperthermic intraoperative peritoneal chemotherapy using cisplatin or mitomycin C is associated with long-term survival. Recent studies on the molecular biology of DMPM have yielded new insights relating to the potentially important role of the phosphatidylinositol 3-kinase/mammalian target of rapamycin and epidermal growth factor receptor pathways in this disease, which may translate into new therapeutic options for patients with DMPM.